Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation

STATUS

Recruiting
participants needed

10
sponsor

Ampio Pharmaceuticals. Inc.

Send

Updated on 19 February 2024

See if I qualify

dyspnea

oximetry

covid-19

SARS

oxygen supplementation

acute respiratory syndrome (sars)

Summary

This is a Phase 1 randomized study to evaluate the safety, tolerability and efficacy of IV Ampion in improving the clinical course and outcomes of patients hospitalized with COVID-19 infection who require supplemental oxygen.

Details

Condition	Covid 19
Age	18years - 89years
Treatment	Standard of Care, Ampion
Clinical Study Identifier	NCT04456452
Sponsor	Ampio Pharmaceuticals. Inc.
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Male or female, 18 years to 89 years old (inclusive)
	Hospitalized and diagnosed with COVID-19, as evaluated by PCR test confirming infection with SARS-COV-2
	Patient is receiving supplemental oxygen (e.g. oxygen saturation (SpO2) <88%, labored breathing, increased respiratory rate, dyspnea on rest or exertion)
	A signed informed consent form from the patient or the patient's legal representative must be available
Exclusion Criteria
	In the opinion of the clinical team, progression to death is imminent and inevitable, irrespective of the provision of treatments
	Patient has severe chronic obstructive pulmonary disease (COPD), chronic renal failure, or significant liver abnormality (e.g. cirrhosis, transplant, etc.)
	Patient is on chronic immunosuppressive medication
	As a result of the medical review and screening investigation, the Principal Investigator considers the patient unfit for the study
	A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate)
	Patient has known pregnancy or is currently breastfeeding
	Participation in another clinical trial
	Baseline QT prolongation

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

oxygen supplementation

acute respiratory syndrome (sars)

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation